Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ: GH )

38.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36
Open 38.10
Bid (Size) 38.10 (15)
Ask (Size) 38.49 (1)
Prev. Close 38.10
Today's Range 38.10 - 38.10
52wk Range 15.81 - 38.53
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
From Guardant Health, Inc.
Via Business Wire
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio? 
Via Benzinga

Performance

YTD
+19.92%
+19.92%
1 Month
+6.96%
+6.96%
3 Month
+78.54%
+78.54%
6 Month
+20.80%
+20.80%
1 Year
+61.78%
+61.78%

More News

Read More
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
From Guardant Health, Inc.
Via Business Wire
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
From COTA Inc.
Via Business Wire
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
Guardant Health Stock Sees RS Rating Jump To 83
Via Investor's Business Daily
Deciphering Disruption: Inside Cathie Wood's Latest Plays
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Why Guardant Health Stock Blasted 13% Higher on Thursday
Via The Motley Fool
HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Guardant Health Rockets 25% On An 'Impressive' Beat Following Exact Sciences' Flop
Via Investor's Business Daily
Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Why Guardant Health Stock Was the Picture of Health Today
Via The Motley Fool
Guardant Health Named to TIME’s List of the Best Inventions of 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
From Guardant Health, Inc.
Via Business Wire
Roberto A. Mignone Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
From Guardant Health, Inc.
Via Business Wire
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
Via Benzinga
Exposures Product Safety
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
From Guardant Health, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.